Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Travis Nielsen

Family Medicine Pocatello, ID Doctor of Osteopathy

NPI 1730340365 CMS profile 1039346

1951 Bench Rd, Suite B, Pocatello, ID 83201

Open in the dashboard

General payments

$4,209

232 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Travis Nielsen of Pocatello, ID is reported in the CMS Open Payments database as having received $4,209 across 232 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $657 36
2024 General $568 30
2023 General $589 28
2022 General $645 37
2021 General $710 36
2020 General $501 31
2019 General $540 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Travis Nielsen
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Travis Nielsen were reported at $657. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Travis Nielsen Family Medicine median Middle half National median
2019 $540 $150 $41–$543 $163
2020 $501 $120 $32–$415 $114
2021 $710 $137 $35–$551 $132
2022 $645 $137 $37–$512 $149
2023 $589 $149 $42–$545 $160
2024 $568 $156 $44–$560 $164
2025 $657 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $605 33 payments
  2. Amgen Inc. $561 34 payments
  3. Astellas Pharma US Inc $393 18 payments
  4. Novo Nordisk Inc $270 18 payments
  5. Grifols USA, LLC $194 10 payments
  6. Lilly USA, LLC $159 12 payments
  7. GlaxoSmithKline, LLC. $141 9 payments
  8. Xeris Pharmaceuticals, Inc. $127 6 payments
  9. Pfizer Inc. $120 8 payments
  10. Vanda Pharmaceuticals Inc. $107 5 payments
  11. Other $1,534 79 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,037 230 payments
  2. Education $100 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $72 1 payment
Products named General payments · program years 2019–2025
  1. Prolia $418 26 payments
  2. EVENITY $379 24 payments
  3. UBRELVY $293 15 payments
  4. Ozempic $213 15 payments
  5. Prolastin-C Liquid $194 10 payments
  6. QULIPTA $184 10 payments
  7. RYBELSUS $176 12 payments
  8. MYRBETRIQ $162 11 payments
  9. Repatha $153 8 payments
  10. VRAYLAR $134 8 payments
  11. Other $3,297 198 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$126,462

Of which drugs: $58,297

Medicare patients

233

Average age 73

Services billed

4,161

126 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Depression 37%
Arthritis 37%
Diabetes 29%
Ischemic heart disease 22%
Osteoporosis 18%
Heart failure 17%
Chronic kidney disease 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 23 2,100 $43,203
Pcv20 vaccine im 90677 Office 30 30 $8,415
Vaccine for influenza for injection into muscle 90653 Office 37 37 $3,027

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $91
$91 13 —
Veozah
  • Astellas Pharma US Inc $52
$52 — —
UBRELVY
  • AbbVie, Inc. $49
$49 — —
QULIPTA
  • AbbVie, Inc. $49
$49 — —
YUPELRI
  • Mylan Specialty L.P. $45
$45 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

232 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record